Preliminary results from KEYNOTE-055: Pembrolizumab after platinum and cetuximab failure in head and neck squamous cell carcinoma (HNSCC).

被引：0
|
作者：
Bauml, Joshua
Seiwert, Tanguy Y.
Pfister, David G.
Worden, Francis P.
Liu, Stephen V.
Gilbert, Jill
Saba, Nabil F.
Weiss, Jared
Wirth, Lori J.
Sukari, Ammar
Kang, Hyunseok
Gibson, Michael K.
Massarelli, Erminia
Powell, Steven Francis
Meister, Amy
Shu, Xinxin
Cheng, Jonathan D.
Haddad, Robert I.
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
[2] Univ Chicago, Chicago, IL 60637 USA
[3] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[4] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[5] Georgetown Univ Hosp, Washington, DC 20007 USA
[6] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA
[9] Massachusetts Gen Hosp, Boston, MA 02114 USA
[10] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[11] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[12] Univ Hosp Case Med Ctr, Cleveland, OH USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Sanford Hlth, Sioux Falls, SD USA
[15] Merck & Co Inc, Kenilworth, NJ USA
[16] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.6011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6011
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Pembrolizumab for cisplatin-failure recurrent/metastatic head and neck squamous cell carcinoma
    Chen, W-C.
    Chang, P. M-H.
    Lee, Y-T.
    Lu, W-B.
    Yang, M-H.
    ANNALS OF ONCOLOGY, 2016, 27
  • [32] A Phase 1 Trial of Pazopanib Added to Cetuximab in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
    Adkins, D.
    Ley, J.
    Wildes, T.
    Trinkaus, K.
    Siegel, M.
    Michel, L.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 94 (04): : 868 - 868
  • [33] Pembrolizumab with or without chemotherapy for first-line treatment of recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): 5-year results from KEYNOTE-048
    Tahara, M.
    Greil, R.
    Rischin, D.
    Harrington, K. J.
    Burtness, B.
    De Castro, G., Jr.
    Psyrri, A.
    Brana, I.
    Neupane, P.
    Bratland, A.
    Fuereder, T.
    Hughes, B. G. M.
    Mesia Nin, R.
    Ngamphaiboon, N.
    Rordorf, T.
    Ishak, W. Z. Wan
    Lin, J.
    Gumuscu, B.
    Lerman, N.
    Soulieres, D.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S844 - S844
  • [34] KEYNOTE-412: Phase III study of pembrolizumab plus chemoradiation vs chemoradiation alone for locally advanced head and neck squamous cell carcinoma (HNSCC)
    Machiels, J-P.
    Licitra, L.
    Tao, Y. G.
    Yen, C-J.
    Rischin, D.
    Waldron, J. N.
    Burtness, B. A.
    Gregoire, V.
    Agarwala, S. S.
    Yorio, J.
    Delord, J-P.
    Aksoy, S.
    Ikeda, S.
    Hong, R-L.
    Ge, J. Y.
    Brown, H.
    Bidadi, B.
    Siu, L. L.
    ANNALS OF ONCOLOGY, 2018, 29 : 398 - 398
  • [35] Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC).
    Uppaluri, Ravindra
    Zolkind, Paul
    Lin, Tianxiang
    Nussenbaum, Brian
    Jackson, Ryan S.
    Rich, Jason
    Pipkorn, Patrik
    Paniello, Randal
    Thorstad, Wade
    Michel, Loren
    Mudianto, Tenny
    Oppelt, Peter John
    Wildes, Tanya Marya
    Dunn, Gavin P.
    Piccirillo, Jay F.
    Kallogjeri, Donna
    Rodig, Scott
    Hagemann, Ian S.
    Chernock, Rebecca
    Adkins, Douglas
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [36] Biomarkers and response to pembrolizumab (pembro) in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
    Chow, Laura Quan Man
    Mehra, Ranee
    Haddad, Robert I.
    Mahipal, Amit
    Weiss, Jared
    Berger, Raanan
    Eder, Joseph Paul
    Burtness, Barbara
    Tahara, Makoto
    Keam, Bhumsuk
    Le, Dung T.
    Muro, Kei
    Geva, Ravit
    Chung, Hyun Cheol
    Lin, Chia-Chi
    Ayers, Mark
    Aurora-Garg, Deepti
    Lunceford, Jared K.
    Cheng, Jonathan D.
    Seiwert, Tanguy Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [37] KEYNOTE-412: Pembrolizumab (pembro) in combination with chemoradiation versus chemoradiation alone in locally advanced head and neck squamous cell carcinoma (LA-HNSCC).
    Machiels, Jean -Pascal H.
    Licitra, Lisa
    Rischin, Danny
    Waldron, John
    Burtness, Barbara
    Gregoire, Vincent
    Shekar, Tulin
    Brown, Holly M.
    Cheng, Jonathan D.
    Siu, Lillian L.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [38] Characteristics of very long responder to maintenance cetuximab after a platinum-cetuximab based chemotherapy for recurrent and/or metastatic head and neck squamous cell carcinomas (RM HNSCC)
    Tardy, Magalie Pascale
    Lescure, Celine
    Doyen, Jerome
    Daste, Amaury
    Lange, Martin
    Saint-Ghislain, Mathilde
    Lefebvre, Gautier
    Sarradin, Victor
    Bozec, Alexandre
    Saada-Bouzid, Esma
    Peyrade, Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [39] Alisertib and pembrolizumab in Rb-deficient head and neck squamous cell carcinomas (HNSCC)
    Johnson, Faye M.
    O'Hara, Madison P.
    Lee, J. Jack
    Qing, Yun
    Tran, Hai
    Ghosh, Soma
    Yapindi, Lacin
    Jiang, Peixin
    Reuben, Alexandre
    Blumenschein, George
    Sastry, Jagannadha
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [40] Gene expression signature after one dose of neoadjuvant pembrolizumab associated with tumor response in head and neck squamous cell carcinoma (HNSCC).
    Kim, Eejung
    Palackdharry, Sarah
    Yaniv, Benyamin
    Mark, Jonathan
    Tang, Alice
    Wilson, Keith
    Patil, Yash
    Janssen, Edith
    Conforti, Laura
    Takiar, Vinita
    Hinrichs, Benjamin
    Wise-Draper, Trisha Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
12345